Seminar: Abuse of a dominant market position

In 2006 the EU Commission fined AstraZeneca €60 million for violating Article 82 of the EC Treaty for abusing pharmaceutical marketing authorization procedures and patent systems in seven Member States in order to prevent or delay entry by generic drug manufacturers. AstraZeneca was found to have engaged in behaviors sometimes called the “evergreening” of patents, by which companies control market access for both generic producers and for parallel traders.

 
Torsdag, 20 januar, 2011 - 12:30 to 14:00

 In 2006 the EU Commission fined AstraZeneca €60 million for violating Article 82 of the EC Treaty for abusing pharmaceutical marketing authorization procedures and patent systems in seven Member States in order to prevent or delay entry by generic drug manufacturers. AstraZeneca was found to have engaged in behaviors sometimes called the “evergreening” of patents, by which companies control market access for both generic producers and for parallel traders.

 Dr. Lilla Montagnani, Bocconi University, will discuss the implications of the EU Commission’s decision, in particular considering whether the decision introduced a new kind of abuse of a dominant position recognized as violating Article 82 and the similarities and differences between this case and American legal doctrine on misuse of intellectual property rights.

 More about Dr. Lilla Montagnani:  http://faculty.unibocconi.eu/marialillamontagnani/

Questions

Lynn Roseberry: lr.jur@cbs.dk

Registration

The seminar is free and open to anyone. Registration is needed - no later than 18 January 2010 - send an e-mail to Kim A. Jørgensen: kaj.jur@cbs.dk

Sidst opdateret: Communications // 31/10/2012